CD8A and cancer: Indeed, active PET uptake and sarcoidosis in LNs can serve as potential prognostic biomarkers to identify which cancer patients will exhibit good oncologic responses to PD-1 antagonists or 4-1BB agonists during treatment.40 However, granuloma development in TDLNs may have contradictory implications due to excessive CD8+ T cell responses and subsequent impairment of sequential CD8+ T cell responses.